FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years.

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Oncolytics Biotech (ONCY – Research Report). The ...

Announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer, reinforcing path to funding of ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced ...

Taken together, the BRACELET-1 results provide compelling support for the potential of pelareorep-based combination therapy ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...